scholarly journals Prevention and Therapeutic Strategies in Endometrial Cancer

10.5772/48791 ◽  
2012 ◽  
Author(s):  
Dan Ancua ◽  
Gheorghe Furu ◽  
Adrian Carabineanu ◽  
Rzvan Ilina ◽  
Octavian Neagoe ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Therapeutic Strategies

Endometrial Cancer: genetic, metabolic characteristics, therapeutic strategies and nanomedicine

2021 ◽  
Vol 28 ◽  
Author(s):  
Yuxuan Cai ◽  
Bei Wang ◽  
Wen Xu ◽  
Kai Liu ◽  
Yisong Gao ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Precancerous Lesions ◽  
Hypoxia Inducible Factor ◽  
The United States ◽  
Genetic Alterations ◽  
Therapeutic Strategies ◽  
Current Application ◽  
Female Population ◽  
Von Hippel Lindau ◽  
Metabolic Characteristics

Background: Endometrial cancer is the fourth most common malignancy in the female population worldwide. It was estimated that 65,620 new cases and 12,590 subsequent deaths occurred in 2020 in the United States. Patients with type II and advanced endometrial cancer do not respond well to the current treatments. Therefore, endometrial cancer should be better understood in order to develop more effective treatments. Objective: To provide an overview of genetic, metabolic characteristics, therapeutic strategies and current application of nanotechnology surrounding endometrial cancer. Method: Relevant articles were retrieved from Pubmed and were systematically reviewed. Results: Hypoxia-inducible factor-1 and Von Hippel-Lindau factor participated in oncogenesis and progression of endometrial cancer, and Nrf2 was associated with oncogenesis. Various genetic alterations were found in endometrial cancer. The examination of the abnormal X chromosome inactivation may help with the diagnosis of endometrial cancer and its precancerous lesions. Some absent tumor suppressor genes, activated oncogenes were revealed by the genetically modified mouse models. Disorders in glucose and lipid metabolism were found in endometrial cancer. Current therapeutic strategies focused on the HIF-1α pathway, the mTOR pathway as well as immunotherapy. Nanotechnology showed great potential in endometrial cancer’s early diagnosis, metastasis determination and treatment. Conclusion: Endometrial cancer has been understood in various aspects, but the underlying mechanisms still remain relatively unknown, which might be the source of novel diagnostic, prognostic and therapeutic targets. Nanomedicine in endometrial cancer is poorly studied, but the current researches showed great results in treating endometrial cancer. It needs further researching.

scholarly journals Endometrial Cancer as a Metabolic Disease with Dysregulated PI3K Signaling: Shedding Light on Novel Therapeutic Strategies

2020 ◽  
Vol 21 (17) ◽  
pp. 6073
Author(s):  
Satoru Kyo ◽  
Kentaro Nakayama
Keyword(s):  
Endometrial Cancer ◽  
Epidemiological Studies ◽  
Reproductive Organs ◽  
Pi3k Pathway ◽  
Therapeutic Strategies ◽  
Pi3k Signaling ◽  
Obese Women ◽  
Alternative Pathways ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

Endometrial cancer (EC) is one of the most common malignancies of the female reproductive organs. The most characteristic feature of EC is the frequent association with metabolic disorders. However, the components of these disorders that are involved in carcinogenesis remain unclear. Accumulating epidemiological studies have clearly revealed that hyperinsulinemia, which accompanies these disorders, plays central roles in the development of EC via the insulin-phosphoinositide 3 kinase (PI3K) signaling pathway as a metabolic driver. Recent comprehensive genomic analyses showed that over 90% of ECs have genomic alterations in this pathway, resulting in enhanced insulin signaling and production of optimal tumor microenvironments (TMEs). Targeting PI3K signaling is therefore an attractive treatment strategy. Several clinical trials for recurrent or advanced ECs have been attempted using PI3K-serine/threonine kinase (AKT) inhibitors. However, these agents exhibited far lower efficacy than expected, possibly due to activation of alternative pathways that compensate for the PIK3-AKT pathway and allow tumor growth, or due to adaptive mechanisms including the insulin feedback pathway that limits the efficacy of agents. Overcoming these responses with careful management of insulin levels is key to successful treatment. Further interest in specific TMEs via the insulin PI3K-pathway in obese women will provide insight into not only novel therapeutic strategies but also preventive strategies against EC.

scholarly journals Enriching Personalized Endometrial Cancer Research with the Harmonization of Biobanking Standards

Cancers ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 1734 ◽  
Author(s):  
Adishesh ◽  
Hapangama
Keyword(s):  
Cancer Research ◽  
Endometrial Cancer ◽  
Gynecological Cancer ◽  
Therapeutic Strategies ◽  
Vital Role ◽  
Rapid Rise ◽  
Diagnostic Strategies ◽  
Collaborative Studies ◽  
Processing And Storage ◽  
And Storage

Endometrial cancer is the commonest gynecological cancer, with an incidence predicted to escalate by a further 50–100% before 2025, due to the rapid rise in risk factors such as obesity and increased life expectancy. Endometrial cancer associated mortality is also rising, depicting the need for translatable research to improve our understanding of the disease. Rapid translation of scientific discoveries will facilitate the development of new diagnostic, prognostic and therapeutic strategies. Biobanks play a vital role in providing biospecimens with accompanying clinical data for personalized translational research. Wide variation in collection, and pre-analytic variations in processing and storage of bio-specimens result in divergent and irreproducible data from multiple studies that are unsuitable for collation to formulate robust conclusions. Harmonization of biobanking standards is thus vital, in facilitating international multi-center collaborative studies with valuable outcomes to improve personalized treatments. This review will detail the pitfalls in the biobanking of biosamples from women with cancer in general, and describe the recent international harmonization project that developed standardized research tools to overcome these challenges and to enhance endometrial cancer research, which will facilitate future development of personalized novel diagnostic strategies and treatments.

scholarly journals Diagnostic and Therapeutic Values of Angiogenic Factors in Endometrial Cancer

Biomolecules ◽  
2021 ◽  
Vol 12 (1) ◽  
pp. 7
Author(s):  
Luka Roškar ◽  
Irena Roškar ◽  
Tea Lanišnik Rižner ◽  
Špela Smrkolj
Keyword(s):  
Endometrial Cancer ◽  
Binding Sites ◽  
Operative Therapy ◽  
Developed Countries ◽  
Therapeutic Strategies ◽  
Angiogenic Factors ◽  
Cancer Growth ◽  
Targeted Cancer Therapy ◽  
Therapeutic Approaches ◽  
Gynecological Malignancy

Endometrial cancer (EC) is the most frequent gynecological malignancy in developed countries and requires a relatively invasive diagnostic evaluation and operative therapy as the primary therapeutic approach. Angiogenesis is one of the main processes needed for cancer growth and spread. The production of angiogenic factors (AFs) appears early in the process of carcinogenesis. The detection of AFs in plasma and tissue and a better understanding of the angiogenic properties of EC may contribute not only to earlier but also more specific diagnosis and consequently tailored and individual therapeutic approaches. AFs and their receptors also have high potential as binding sites for targeted cancer therapy. In this review, we discuss angiogenesis in EC and the characteristics of the AFs that most contribute to angiogenesis in EC. We also highlight therapeutic strategies that target angiogenesis as potential EC therapy.

Sign in / Sign up

Export Citation Format

Share Document